Setback for improved therapy in advanced urothelial cancer
Neither mono nor dual immune checkpoint inhibitor therapy improved survival in multi-nation study
AusDoc brings you the latest news from the European Society for Medical Oncology virtual congress 2020.
A bid to harness immune checkpoint blockade to improve first-line therapy for patients with untreated metastatic urothelial cancer has faltered with a phase 3 trial failing to meet primary endpoints, a conference has heard.
The DANUBE trial comparing efficacy of PD-L1 inhibitor durvalumab alone or with CTLA-4 inhibitor tremelimumab against standard-of-care chemotherapy (gemcitabine plus cisplatin or carboplatin), is the first of several trials exploring the approach, the researchers said.
The open-label, randomised, controlled phase 3 trial was conducted at 224 centres in 23 countries.
